India, Oct. 1 -- Swiss drug major Roche Holding AG (RHHBY,RO.SW,ROG.SW) announced Thursday that giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA.
The detailed results from the evERA Breast Cancer study were published in The New England Journal of Medicine.
The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of November 30 and in advanced disease of December 18.
giredestrant is an investigational oral selective oestrogen receptor degrader or SERD.
The evERA trial is evaluating giredestrant in combination with everolimus in people with oestrogen receptor (ER)-positive locally advanced or metastatic breast cancer who had disease pr...